Maxim Group analyst Jason Kolbert weighed in on Neuralstem (NYSE: CUR) after the company reported ALS phase II data this ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE